Beta Drugs is a compounder only if three things happen: branded oncology and Nivin keep growing above the market, CMO and exports convert current guidance into revenue, and the API and intermediates plant lowers cost without regulatory delay. The business is no longer a single domestic oncology formulator. H1 FY27 revenue grew 29.2%, EBITDA margin was 23.18% and PAT rose 45% to INR34 crore. Management guides FY27 revenue to INR535 crore plus, 20-25% growth over three to five years and 23-24% margins. Those are guidance, not achieved annual outcomes.
The economics are improving with mix. Management says branded gross margin is about 70%, CMO about 50% and exports 55-60%. A shift toward branded, Nivin and exports should lift EBITDA even without cost cuts. API backward integration adds a second lever because it can reduce imported intermediate costs and support dossiers. H1 FY27 reported EBITDA margin was 23.18%, but that includes other income; excluding other income, the margin was 22%. The margin case therefore depends on mix and operating leverage, not only on the reported headline.
Own brands are the core. H1 FY27 own-brand sales grew 17%, but Q2 was flat after a temporary shutdown shifted INR6-7 crore into H2. Management expects H2 own-brand sales of INR80 crore versus INR62 crore prior and retains a INR150 crore FY27 target. Branded oncology is guided at 20-22% growth, with four launches in FY27 and six more planned. The near-term falsifier is H2 own-brand sales below INR80 crore, which would put both the INR150 crore own-brand target and the INR535 crore plus consolidated target at risk.
Nivin is the second engine. Beta acquired 66.1% for INR69.4 crore at a INR105 crore valuation, closed in April 2026. Nivin reported FY26 revenue of about INR43 crore and H1 FY27 sales of INR31 crore, up 75% from INR18 crore. The prescriber base rose 60% and the top five brands are 63% of sales. Management guides 30-35% growth over two to three years and 23-25% EBITDA after synergies from 18-18.5% now. The remaining 33% is open-ended. The falsifier is growth below 30% or no margin uplift as Beta's corporate hospital access is applied.
CMO is the third engine and the guidance has changed materially. May 2026 guided CDMO growth at 5-6%. Q2 FY27 reports CMO growth of 21% in H1 and guides FY27 CMO revenue at INR180-190 crore. Two to three new Indian partners were added, and NDDS products carry higher margins than standard CMO. Platin API supply remains constrained, but management says the FY27 guidance can be met without platins. The falsifier is CMO revenue below INR180 crore or a return to low single-digit growth if partner orders do not repeat.
Exports are the fourth engine and the most volatile. H1 FY27 exports were INR43 crore. Management guides FY27 exports at INR90-100 crore and about INR300 crore over three to four years at a roughly 30% CAGR. The earlier 50% FY27 growth target and INR105-110 crore guide were reset lower. The pipeline is large: 35 new registrations were received and 872 registrations are in the pipeline for the next two to three years. The business is tender-driven, so timing can slip. The falsifier is FY27 exports below INR90 crore or another year of tender delays.
API and intermediates are the cost lever. API sales grew 29% in H1 FY27. Beta bought an existing intermediates/KSM plant for INR9 crore and budgeted INR15-17 crore for building and machinery, for a disclosed total of INR27 crore including land. The plant is targeted live by January 2027 with about 20 intermediates for captive API and possible external sales. Management expects a 1-1.5% margin benefit subject to commercial yields. The falsifier is a commissioning slip beyond January 2027 or yields that do not deliver the cost benefit.
Derma is optionality. It was EBITDA positive in FY26. H1 FY27 PCPM rose 30% to an average INR2.5 lakh, and the first high-end European cosmetics consignment was registered, with licensed launches due in December 2026. May 2026 guidance targets INR50 crore of derma revenue over three years and 12-14% EBITDA at INR50-60 crore sales. The segment is still small and competitive. The falsifier is derma revenue stalling below the INR50 crore path or gross margin remaining at the lower 57-58% level.
The regulatory gate is the EU GMP audit. May 2026 expected the audit in the first week of September 2026 after three dossiers. By Q2 FY27 four dossiers were filed and management said the audit could come in the next two to four months. Approval would support regulated-market formulation exports and management's 23-25% export margin aspiration. The falsifier is another delay beyond the next few months, which would defer the regulated export contribution.
Capital allocation is active but still modest. The Nivin acquisition was INR69.4 crore. The intermediate plant is INR27 crore. The R&D and corporate office land is now held for disposal after the plan was dropped, with no disclosed sale value. CCDs converted in early FY27, the cost of debt is 8-9%, and receivables were 116 days versus 113 days at 31 March 2026. Institutional branded tenders of INR20-25 crore carry 100-120 day terms. These are manageable but absorb cash as the institutional mix rises.
Management delivery is mixed. FY26 revenue missed the revised INR400-420 crore range and closed at INR396 crore. Export guidance for FY27 has been reset lower. The EU audit has slipped repeatedly. Against that, Nivin and derma have delivered, H1 FY27 growth is strong, and FY27 targets are now explicit. The thesis is therefore a delivery compounder, not a promise compounder. The evidence supports a business with multiple growth engines and improving economics, but the next twelve months must show H2 own-brand recovery, export conversion, CMO delivery, Nivin margin synergy and the intermediate plant start.
On current evidence, Beta can compound if FY27 revenue reaches INR535 crore plus and margins hold at 23-24% including other income. The key falsifiers are H2 own-brand below INR80 crore, exports below INR90 crore, CMO below INR180 crore, Nivin growth below 30%, an intermediate plant slip beyond January 2027, or a further EU audit delay. No price target or valuation judgment is implied.
Beta Drugs is an oncology-focused pharmaceutical company that manufactures and markets anti-cancer formulations across solid tumour, haematology and supportive care, and ranks among the top 10 in the domestic cytotoxic market. It also runs a CDMO business, an export franchise, an API and intermediates operation, a dermatology and cosmetology division, and, since April 2026, a 66.1% stake in Nivian Lifesciences, an IVF and fertility business. Its products are sold across major government and priv...
Read the full report →capex, margin expansion, acquisition inorganic, debt reduction
Explicit forward guidance from the Q2 FY27 call: FY27 revenue of INR535 crore plus; 20-25% growth over three to five years with sustained EBITDA margins of 23-24%; own-brand sales of INR150 crore in FY27 with branded oncology growth of 20-22%; CMO revenue of INR180-190 crore in FY27; exports of INR90-100 crore in FY27 and about INR300 crore over three to four years at a roughly 30% CAGR; Nivin growth of 30-35% over the next two to three years; intermediates/KSM plant live by January 2027; EU GMP audit expected in the next two to four months.
Guidance maintainedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Beta Drugs Ltd and 4,900+ companies.
5-day free pass. No card required.